J.P. Morgan 38th Annual Healthcare Conference, San Francisco

January 13, 2020 | Investor

Bavarian Nordic has undergone a significant transformation over the past few months, driven by the acquisition of two established commercial vaccines (rabies & tick-borne encephalitis) and an FDA approval (smallpox/monkeypox), which are projected to dramatically accelerate the Company’s path to profitability. 

If you are interested in learning more about Bavarian Nordic and our vaccine portfolio, management will be holding meetings at the J.P. Morgan Healthcare Conference in San Francisco, January 13-15, 2020.

To request a meeting, please contact: Graham Morrell –